WASHINGTON - Pfizer’s CEO says "it’s a question of days, not weeks" before the company and German partner BioNTech submit data to U.S.
regulators for federal authorization of a COVID-19 vaccine for children age 5 to 11.That would be an important step toward starting vaccinations for those youngsters, especially with kids now back in school and the delta variant resulting in a big jump in pediatric infections.Pfizer said last week that its vaccine works for that age group and that it tested a much lower dose of the vaccine that’s already available for anyone 12 and older.